Çocukluk Yaş Grubunda Kolon Striktürü İle Prezente Olan Crohn Hastalığı: Nadir Bir Olgu

Crohn Hastalığı (CH) tüm gastrointestinal sistemi transmural ve segmental olarak tutabilen multisistemik bir hastalık olup tutulum yerine göre çok çeşitli semptomlar ile hastalar başvurabilmektedir. On beş yaşında şiddetli karın ağrısı ile başvuran hastada yapılan incelemelerde sağ kolonda darlık gözlenmiş olup CH ile uyumlu saptandı. İzleminde cilde fistülize olan, karın içinde abse gelişen hastanın tedavisinde kortikosteroid, azathiopurin, mesalazin, metotreksat, infliksimab ve antibiyotik tedavisi ile düzelme sağlandı. İzlemde şikayetleri gerileyen hastanın kontrollerinde karın içi abseleri ve kolon darlığı geriledi. Crohn Hastalığında, daha çok erişkin dönemde geç dönem komplikasyonu olarak karşılaştığımız bağırsak striktürü ile prezente olan CH saptadığımız çocuk hastayı sunmak istedik.ABSTRACT Crohn’s Disease (CD) is a multisystemic disease which may affect gastrointestinal system transmural and segmental and patients may present with any kind of symptoms. An investigation on 15-year-old patient who presented with severe abdominal pain revealed narrowing in right colon and found consistent with CD. The patient who devepoled an abcess fistulized to the skin during the follow-up showed improvement after treatment with corticosteroid, azathioprine, mesalazine, methotrexate, infliximab, and antibiotics. During follow-up, intra-abdominal abcesses and narrowing of the colon regressed along with patient’s symptoms. We wanted to present this case where our patient was diagnosed with CD after presenting with colon stricture which is more commonly seen as late stage complication in adult CD.  
Anahtar Kelimeler:

Crohn Hastalığı, çocuk, kolon

___

  • 1. Yuan Q, Winter HS. Crohn’s disease. In: Guandalini S (ed). Textbook of Pediatric Gasroenterology and Nutrition. London, Newyork: Taylor and Francis, 2004; 347-78.
  • 2. Panes J, Gomollon F, Taxonera C, Hinojosa J, Clofent J, Nos P . Crohn's disease: a review of current treatment with a focus on biologics. Drugs. 2007;67(17):2511-37.
  • 3. Thoreson R, Cullen JJ. Pathophysiology of inflammatory bowel disease: an overview. Surg Clin North Am. Jun 2007. 87(3):575-85.
  • 4. Wilkins T, Jarvis K, Patel J. Diagnosis and management of Crohn's disease. Am Fam Physician. 2011 Dec 15. 84(12):1365-75.
  • 5. Nikolaus S, Schreiber S. Diagnostics of inflammatory bowel disease. Gastroenterology. Nov 2007. 133(5):1670-89.
  • 6. Cassidy JT, Petty RE, Chronic artritis in childhood, In: Cassidy JT, Petty RE, eds. Textbook of Pediatric Rheumatology. 5th ed. Philadelphia, Pa. Saunders, 2005: 206-60.
  • 7. Saps M, Di Lorenzo C. Diagnosis and managing functional symptoms in the child with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2004; 39(3): 760-2
  • 8. Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr. 106(4):661-73.
  • 9. Leichtner AM, Higuchi L. Ulcerative colitis. In: Walker WA, Goulet O, Kleinman RE, Sherman PM, Schneider BL, Sanderson IR (ed) s. Pediatric Gasrointestinal Disease. Fourth ed. Canada: BC Decker, 2004; 825-49
  • 10. Panes J, Gomollon F, Taxonera C, et al. Crohn's disease: a review of current treatment with a focus on biologics. Drugs. 2007. 67(17):2511-37.
  • 11. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337(15):1029-35.
  • 12. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126 (2): 402-13.
  • 13. Akobeng AK, Richmond K, Miller V, Thomas AG. Effect of exclusive enteral nutrtional treatment on plasma antioxydant concentrations in childhood Crohn’s disease. Clinical Nutrition 2007; 26(1): 51-6.